Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis
Advances in Therapy, October 2024
Several novel therapies that modulate the immune system have been approved by the US Food and Drug Administration (FDA) to treat generalized myasthenia gravis (gMG), a rare neuromuscular disorder that can lead to life-threatening complications. However, no head-to-head clinical trials have directly compared these therapies. Additionally, assessing the economic value of these treatments could provide important insights.
To evaluate both the risk-benefit profiles and economic value of these therapies, Analysis Group Managing Principal Hongbo Yang, Manager Mandy Du, and Senior Analyst Xin Chen collaborated with researchers from Argenx; Virginia Commonwealth University; University at Buffalo; University of California, Irvine Medical Center; and University of Naples Federico II on a network meta-analysis of clinical trial data. The investigators compared differences in efficacy and safety outcomes between five gMG treatments and estimated the costs associated with each treatment. In an article reporting their findings, study investigators describe their evaluation of efgartigimod, eculizumab, ravulizumab, rozanolixizumab, and zilucoplan for the treatment of gMG. They conclude that all therapies are reasonably safe and more effective than a placebo, with efgartigimod demonstrating a larger treatment effect on most efficacy measures and a more favorable economic value, as compared to the other treatments studied.
The article, “Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis,” was published in Advances in Therapy.
Authors
Smith AG, Wolfe GI, Habib AA, Qi CZ, Yang H, Du M, Chen X, Gelinas D, Brauer E, Phillips G, Saccà F